IL17C and neoplasm: To delineate the role of upregulated VEGF production in tumorigenesis of IL-17C-treated xenografts, we used the VEGFR2 inhibitor Ki8751 (10 μg/tumor, peritumoral injection) to block the biological activity of VEGF.